Status:
COMPLETED
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborating Sponsors:
PETHEMA (Program for the Study and Treatment of Haematological Malignances)
Conditions:
Hematological Malignancy
Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for fever in neutrope...
Eligibility Criteria
Inclusion
- Patients with hematological malignancy or those who had undergone stem cell transplantation for neoplastic disease.
- Fever (\>38ºC)
- Neutropenia (absolute neutrophil count \< 500 or \< 1000 anticipated to fall below 500 cells within 24-48 hours).
Exclusion
- Known allergy to any of the antibiotics used in this trial
- A high probability of death within 48 hours
Key Trial Info
Start Date :
July 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
801 Patients enrolled
Trial Details
Trial ID
NCT00195533
Start Date
July 1 2001
End Date
March 1 2005
Last Update
November 16 2009
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
A Coruña, Spain
2
Alcalá de Henares, Spain
3
Alzira, Spain
4
Barcelona, Spain